Table 1.
Characteristics of Patients With IBD Undergoing Biologic Therapy According to Serology Test Results
| Characteristics | n | Serology test results |
P value | |
|---|---|---|---|---|
| Negative (n = 71) | Positive (n = 19) | |||
| Sex, n (%) | ||||
| Female | 90 | 29 (40.8) | 13 (68.4) | .032a |
| Male | 42 (59.2) | 6 (31.6) | ||
| Age, y, median (IQR) | 90 | 34.0 (19.0–47.0) | 50.0 (28.0–57.0) | .020a |
| <28a | 28 (39.4) | 4 (21.1) | .019a | |
| 28–47a | 24 (33.8) | 3 (15.8) | ||
| ≥47a | 19 (26.8) | 12 (63.2) | ||
| IBD type, n (%) | ||||
| Ulcerative colitis | 90 | 30 (42.3) | 5 (26.3) | .21 |
| Crohn’s disease | 41 (57.7) | 14 (73.7) | ||
| Biologic therapy, n (%) | ||||
| Anti-TNF, n (%) | 90 | 59 (83.1) | 15 (78.9) | 0.67 |
| Adalimumab | 30 (42.3) | 10 (52.6) | .42 | |
| Infliximab | 28 (39.4) | 5 (26.3) | .29 | |
| Golimumab | 1 (1.4) | 0 (0.0) | .99 | |
| Anti-integrin (vedolizumab) , n (%) | 90 | 8 (11.3) | 1 (5.3) | .68 |
| Anti-IL12/23 (ustekinumab) , n (%) | 90 | 4 (5.6) | 3 (15.8) | .16 |
| Monotherapy/combination therapy, n (%) | 90 | 13 (18.3) | 5 (26.3) | 0.44 |
| Contact, n (%) | 86 | 2 (3.0) | 2 (10.5) | 0.21 |
| Symptoms, n (%) | 87 | 4 (5.9) | 8 (42.1) | <.001a |
| Fever | 12 | 2 (50.0) | 7 (87.5) | 0.24 |
| Cough | 12 | 3 (75.0) | 3 (37.5) | 0.55 |
| Dysgeusia/anosmia | 12 | 0 (0.0) | 5 (62.5) | .081 |
NOTE. Data are expressed as column percentages. Percentages may not reach 100% because of rounding
IL, interleukin; IQR, interquartile range; TNF, tumor necrosis factor.
a
Tertiles of age distribution.